Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants

Cell Death and Disease

Volumn 1, Issue 10, 2010, Pages

  Reis, C R ^a   Van Der Sloot, A M ^b   Natoni, A ^c   Szegezdi, E ^c   Setroikromo, R ^a   Meijer, M ^d   Sjollema, K ^d   Stricher, F ^b   Cool, R H ^a,e   Samali, A ^c   Serrano, L ^f   Quax, W J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b CENTRE FOR GENOMIC REGULATION CRG   (Spain)

^c NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e Triskel Therapeutics BV   (Netherlands)

^f UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

Apoptosis; Death receptors; Homotrimerization; TRAIL

Indexed keywords

CASPASE 8; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEIN; DEATH RECEPTOR 4; DEATH RECEPTOR 5; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ANTINEOPLASTIC AGENT; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

APOPTOSIS; ARTICLE; BINDING AFFINITY; CELL VIABILITY; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; DRUG SELECTIVITY; ENZYME ACTIVATION; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN PURIFICATION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; SURFACE PLASMON RESONANCE; AMINO ACID SUBSTITUTION; BIOLOGY; CHEMISTRY; FEMALE; GENETICS; KINETICS; METABOLISM; MUTATION; OVARY TUMOR; PROTEIN BINDING; PROTEIN MULTIMERIZATION; TUMOR CELL LINE;

AMINO ACID SUBSTITUTION; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; FEMALE; HUMANS; KINETICS; MUTATION; OVARIAN NEOPLASMS; PROTEIN BINDING; PROTEIN MULTIMERIZATION; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECOMBINANT PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 79958750290     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2010.61     Document Type: Article

References (36)

1. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J et al. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276: 111-113. (Pubitemid 27161256)
2. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997; 277: 818-821. (Pubitemid 27366733)
3. Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity 1997; 7: 821-830. (Pubitemid 28064895)
4. Kuang AA, Diehl GE, Zhang J, Winoto A. FADD is required for DR4- and DR5-mediated apoptosis: lack of trail-induced apoptosis in FADD-deficient mouse embryonic fibroblasts. J Biol Chem 2000; 275: 25065-25068.
5. Schneider P, Thome M, Burns K, Bodmer JL, Hofmann K, Kataoka T et al. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity 1997; 7: 831-836. (Pubitemid 28064896)
6. Bodmer JL, Holler N, Reynard S, Vinciguerra P, Schneider P, Juo P et al. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2000; 2: 241-243.
7. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A. Apo2L/ TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000; 12: 611-620.
8. Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000; 12: 599-609.
9. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003; 10: 66-75. (Pubitemid 36511833)
10. Kimberley FC, Screaton GR. Following a TRAIL: update on a ligand and its five receptors. Cell Res 2004; 14: 359-372. (Pubitemid 43231798)
11. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997; 277: 815-818. (Pubitemid 27366732)
12. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155-162.
13. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001; 7: 383-385.
14. Clancy L, Mruk K, Archer K, Woelfel M, Mongkolsapaya J, Screaton G et al. Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc Natl Acad Sci USA 2005; 102: 18099-18104. (Pubitemid 41798508)
15. Merino D, Lalaoui N, Morizot A, Schneider P, Solary E, Micheau O. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol 2006; 26: 7046-7055. (Pubitemid 44477684)
16. Kelley RF, Totpal K, Lindstrom SH, Mathieu M, Billeci K, Deforge L et al. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem 2005; 280: 2205-2212.
17. MacFarlane M, Kohlhaas SL, Sutcliffe MJ, Dyer MJ, Cohen GM. TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res 2005; 65: 11265-11270. (Pubitemid 41821680)
18. Tur V, van der Sloot AM, Reis CR, Szegezdi E, Cool RH, Samali A et al. DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design. J Biol Chem 2008; 283: 20560-20568.
19. van der Sloot AM, Tur V, Szegezdi E, Mullally MM, Cool RH, Samali A et al. Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. Proc Natl Acad Sci USA 2006; 103: 8634-8639. (Pubitemid 43878072)
20. Almasan A, Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 2003; 14: 337-348. (Pubitemid 36693152)
21. Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001; 7: 954-960. (Pubitemid 32756434)
22. MacFarlane M, Inoue S, Kohlhaas SL, Majid A, Harper N, Kennedy DB et al. Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death Differ 2005; 12: 773-782. (Pubitemid 40945984)
23. Reis CR, van der Sloot AM, Szegezdi E, Natoni A, Tur V, Cool RH et al. Enhancement of antitumor properties of rhTRAIL by affinity increase toward its death receptors. Biochemistry 2009; 48: 2180-2191.
24. Thomas LR, Henson A, Reed JC, Salsbury FR, Thorburn A. Direct binding of Fasassociated death domain (FADD) to the tumor necrosis factor-related apoptosis-inducing ligand receptor DR5 is regulated by the death effector domain of FADD. J Biol Chem 2004; 279: 32780-32785. (Pubitemid 39014737)
25. Hellwig CT, Kohler BF, Lehtivarjo AK, Dussmann H, Courtney MJ, Prehn JH et al. Real time analysis of tumor necrosis factor-related apoptosis-inducing ligand/ cycloheximide-induced caspase activities during apoptosis initiation. J Biol Chem 2008; 283: 21676-21685.
26. Garcia-Calvo M, Peterson EP, Leiting B, Ruel R, Nicholson DW, Thornberry NA. Inhibition of human caspases by peptide-based and macromolecular inhibitors. J Biol Chem 1998; 273: 32608-32613. (Pubitemid 28557641)
27. McStay GP, Salvesen GS, Green DR. Overlapping cleavage motif selectivity of caspases: implications for analysis of apoptotic pathways. Cell Death Differ 2008; 15: 322-331.
28. Zhang XD, Franco A, Myers K, Gray C, Nguyen T, Hersey P. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res 1999; 59: 2747-2753. (Pubitemid 29269125)
29. Mahalingam D, Szegezdi E, Keane M, Jong S, Samali A. TRAIL receptor signalling and modulation: Are we on the right TRAIL? Cancer Treat Rev 2009; 35: 280-288.
30. Duiker EW, de Vries EG, Mahalingam D, Meersma GJ, Boersma-van Ek W, Hollema H et al. Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model. Clin Cancer Res 2009; 15: 2048-2057.
31. Truneh A, Sharma S, Silverman C, Khandekar S, Reddy MP, Deen KC et al. Temperaturesensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J Biol Chem 2000; 275: 23319-23325. (Pubitemid 30646233)
32. Mongkolsapaya J, Grimes JM, Chen N, Xu XN, Stuart DI, Jones EY et al. Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation. Nat Struct Biol 1999; 6: 1048-1053. (Pubitemid 29519600)
33. Guerois R, Nielsen JE, Serrano L. Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations. J Mol Biol 2002; 320: 369-387. (Pubitemid 34722226)
34. Schymkowitz JW, Rousseau F, Martins IC, Ferkinghoff-Borg J, Stricher F, Serrano L. Prediction of water and metal binding sites and their affinities by using the Fold-X force field. Proc Natl Acad Sci USA 2005; 102: 10147-10152. (Pubitemid 41023340)
35. Reis CR, van Assen AH, Quax WJ, Cool RH. Unraveling the binding mechanism of trivalent tumor necrosis factor ligands and their receptors. Mol Cell Proteomics [Epub ahead of print 17 September 2010].
36. Rehm M, Dussmann H, Janicke RU, Tavare JM, Kogel D, Prehn JH. Single-cell fluorescence resonance energy transfer analysis demonstrates that caspase activation during apoptosis is a rapid process. Role of caspase-3. J Biol Chem 2002; 277: 24506-24514. (Pubitemid 34951976)